TRMT2A

Across TCGA pan-cancer cohorts, TRMT2A RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of TRMT2A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TRMT2A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRMT2A is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

KIRC, COAD, and BLCA are the cancer types where TRMT2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRMT2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+0.881	<.001	12	view →
COAD	Female	All	+1.149	<.001	11	view →
BLCA	Male	All	+0.939	<.001	10	view →
HNSC	Male	III,IV	+0.936	<.001	10	view →
LIHC	Female	II,III,IV	+1.110	<.001	9	view →
STAD	Male	II,III,IV	+0.840	<.001	8	view →
READ	Female	All	+1.127	<.001	7	view →
LUAD	Female	All	+0.554	<.001	7	view →
CHOL	Male	All	+1.676	<.001	5	view →
LUSC	All	All	+0.874	<.001	5	view →
KICH	Female	All	−0.692	<.001	4	view →
ESCA	All	All	+0.652	.002	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

TRMT2A–KIRC

Open the KIRC breakdown →